# Cyclosporine Atopica Dose: Immune-Mediated Disease Dose Monitoring


## Key Takeaways

-   Cyclosporine (Atopica) is a calcineurin inhibitor immunosuppressant with a narrow therapeutic window, necessitating individualized dosing and careful monitoring for immune-mediated diseases in dogs and cats.
-   Initial dosing typically ranges from 5 mg/kg once daily for dermatologic conditions to 5-10 mg/kg daily for more severe immune-mediated diseases, often in conjunction with other immunosuppressants.
-   Therapeutic Drug Monitoring (TDM), primarily through trough level measurements (target 100-500 ng/mL, lab-dependent), is crucial for optimizing efficacy and minimizing toxicity, especially for conditions like IMHA and IBD.
-   Adverse effects, particularly nephrotoxicity and hepatotoxicity, are significant concerns and require regular monitoring of renal and hepatic function via serum chemistry panels and urinalysis.
-   Critical drug interactions exist, notably with azole antifungals (e.g., ketoconazole), which can drastically increase cyclosporine blood levels and risk of toxicity, mandating thorough medication review by veterinarians.
-   Dose adjustments are guided by clinical response and TDM results, with a focus on using the lowest effective dose to maintain remission and prevent long-term organ damage, and owners must never adjust doses without veterinary consultation.

---

**Direct answer:** Cyclosporine (often sold under the brand name Atopica in veterinary medicine) is a potent calcineurin inhibitor immunosuppressant used to treat a range of immune-mediated diseases in dogs and cats. There is no single "one-size-fits-all" dose. The dose is highly individualized, typically starting at 5 mg/kg once daily for dermatologic conditions, but it can vary from 3 to 10 mg/kg depending on the specific disease, the patient's response, and the need for therapeutic drug monitoring (TDM). Monitoring is not just recommended; it is often essential to balance efficacy against the risk of severe side effects, especially for conditions like immune-mediated hemolytic anemia (IMHA) or inflammatory bowel disease (IBD).

**Owner Triage Summary:** If your pet has been prescribed cyclosporine (Atopica), you must understand that this is a powerful medication requiring strict veterinary supervision. Do not adjust the dose without consulting your veterinarian. If your pet experiences severe vomiting, diarrhea (or diarrhoea), seizures, or signs of a new infection (fever, lethargy, loss of appetite), contact your veterinarian or an emergency clinic immediately. This article explains how veterinarians determine and monitor the dose to keep your pet safe.

---

## At a Glance: Cyclosporine Dosing and Monitoring

| Parameter | Typical Veterinary Recommendation | Clinical Rationale |
| :--- | :--- | :--- |
| **Initial Dose (Dermatology)** | 5 mg/kg PO once daily | Standard starting point for atopic dermatitis; may be given as a split dose (e.g., 2.5 mg/kg twice daily) to reduce GI upset. |
| **Initial Dose (Immune-Mediated)** | 5-10 mg/kg PO once daily or divided | Often combined with other immunosuppressants (e.g., corticosteroids) for rapid control of severe disease. |
| **Dose Adjustments** | Based on clinical response and trough levels | Trough levels (drawn just before the next dose) are used to guide therapy. |
| **Target Trough Level (General)** | 100-500 ng/mL (varies by lab and disease) | Levels are kept in this range to maximize efficacy while minimizing toxicity. |
| **Monitoring Frequency** | Initially: every 1-2 weeks; Stable: every 3-6 months | Includes serum chemistry, CBC, and trough levels. |
| **Key Drug Interactions** | Azole antifungals (e.g., ketoconazole), amphotericin B, and others | These drugs can significantly increase cyclosporine blood levels, increasing the risk of toxicity. |

---

## Understanding Cyclosporine and Its Mechanism of Action

Cyclosporine A (CsA) is a cornerstone of immunosuppressive therapy in both human and veterinary medicine [<a href="#ref-1">1</a>]. It is a calcineurin inhibitor. In simple terms, it blocks a specific pathway inside T-lymphocytes (a type of white blood cell) that is critical for their activation. When T-cells are activated, they release cytokines (like interleukin-2) that drive the inflammatory and immune responses. By inhibiting this process, cyclosporine effectively "calms down" the immune system, making it useful for conditions where the immune system is overactive or attacking the body's own tissues [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>].

In veterinary medicine, its use has been adapted from human transplantation protocols [<a href="#ref-2">2</a>]. While it is most famous for preventing organ transplant rejection, it is now widely used "off-label" (or extra-label) for a variety of immune-mediated diseases in pets, including:
- **Atopic Dermatitis:** Chronic skin allergies.
- **Inflammatory Bowel Disease (IBD):** Chronic gastrointestinal inflammation.
- **Immune-Mediated Hemolytic Anemia (IMHA):** The immune system destroys red blood cells.
- **Immune-Mediated Thrombocytopenia (IMT):** The immune system destroys platelets.
- **Autoimmune Skin Diseases:** Such as lupus or pemphigus.
- **Other Conditions:** Such as certain forms of kidney disease (e.g., protein-losing nephropathy) and hepatobiliary disease.

The challenge, as highlighted in human medicine, is that cyclosporine has a **narrow therapeutic window** [<a href="#ref-1">1</a>]. This means the difference between a dose that works and a dose that causes harm is small. Furthermore, there is **marked interindividual pharmacokinetic variability**, meaning that two animals of the same breed, age, and weight can have vastly different blood levels of the drug after receiving the exact same dose [<a href="#ref-1">1</a>]. This is why therapeutic drug monitoring (TDM) is so valuable.

---

## The Rationale for Therapeutic Drug Monitoring (TDM)

The core principle of "Cyclosporine Atopica Dose: Immune-Mediated Disease Dose Monitoring" is that we do not just dose the pet; we dose the *individual patient*. TDM involves measuring the concentration of cyclosporine in the blood to make informed dose adjustments.

### Why is TDM Necessary?

1.  **Narrow Therapeutic Window:** As noted, cyclosporine has a narrow window between therapeutic and toxic levels [<a href="#ref-1">1</a>].
2.  **High Pharmacokinetic Variability:** Absorption, distribution, metabolism, and excretion can vary significantly between individual animals. Factors like food, gastrointestinal health, and concurrent medications all play a role [<a href="#ref-1">1</a>].
3.  **Predicting Toxicity:** High blood levels of cyclosporine are directly associated with an increased risk of adverse effects, most notably kidney injury (nephrotoxicity) and liver injury (hepatotoxicity) [<a href="#ref-1">1</a>, <a href="#ref-3">3</a>].
4.  **Predicting Efficacy:** Conversely, levels that are too low may not adequately suppress the immune system, leading to treatment failure or disease flares.
5.  **Managing Drug Interactions:** Cyclosporine is metabolized by the cytochrome P450 enzyme system in the liver. Many other drugs can either inhibit or induce these enzymes, leading to dangerous increases or decreases in cyclosporine levels. For example, azole antifungals (like ketoconazole and itraconazole) are potent inhibitors of this system and can dramatically increase cyclosporine levels [<a href="#ref-1">1</a>].

### How is TDM Performed?

The most common method is measuring a **trough level**. This is a blood sample taken right before the next dose is due. The trough level represents the lowest concentration of the drug in the bloodstream during a dosing interval. It is a reliable indicator of the drug's steady-state level and correlates well with both efficacy and toxicity.

Another method is measuring an **AUC (Area Under the Curve)**. This involves taking multiple blood samples over a 12- or 24-hour period to calculate the total drug exposure. While more accurate, it is more expensive and invasive, so it is less commonly performed in general practice.

---

## Evidence-Based Dosing for Specific Conditions

While the starting dose is often similar, the target levels and the duration of therapy can differ based on the underlying disease.

### Atopic Dermatitis and Skin Allergies

For canine atopic dermatitis, the standard label dose for Atopica is **5 mg/kg once daily**. Many veterinary dermatologists recommend giving it with food to reduce gastrointestinal side effects. Clinical improvement is often seen within 4 to 6 weeks. Once the skin condition is controlled, the dose is often tapered to the lowest effective frequency, such as every other day or twice a week. TDM is less commonly used for this indication, as the therapeutic index is wider and the end-point (skin health) is easily observable. However, monitoring for side effects like gastrointestinal upset is still crucial.

### Inflammatory Bowel Disease (IBD)

For IBD, cyclosporine is often used in cases that are refractory to other immunosuppressants like corticosteroids. A dose of **5 mg/kg once daily** is a common starting point. TDM is more frequently recommended here because the clinical response can be slower and less obvious. Achieving a therapeutic trough level is often necessary to induce remission. If the patient does not respond within a few weeks, a trough level can tell you if the drug is being absorbed adequately. If the level is low, the dose may be increased, or the drug may be changed.

### Immune-Mediated Hemolytic Anemia (IMHA) and Thrombocytopenia (IMT)

These are life-threatening conditions where the immune system is destroying red blood cells or platelets. Treatment must be rapid and aggressive. Cyclosporine is often used as a **second-line or adjunctive therapy** alongside high-dose corticosteroids and sometimes other drugs like mycophenolate mofetil.

In these critical cases, the dose is often at the higher end of the range, **5 to 10 mg/kg per day**, and TDM is strongly recommended. The goal is to achieve a rapid and profound immunosuppressive effect to halt the destruction of blood cells. Monitoring trough levels helps ensure the drug is in the therapeutic range quickly, as a sub-therapeutic level in the first few days of treatment could be fatal.

### Other Autoimmune Diseases

For conditions like systemic lupus erythematosus (SLE) or immune-mediated polyarthritis, cyclosporine is sometimes used as a steroid-sparing agent. The dose is typically **5 mg/kg once daily**, and TDM is used to guide long-term therapy, especially if the patient is not responding or if there are concerns about side effects.

---

## The Critical Role of Concurrent Medications

One of the most dangerous aspects of cyclosporine therapy is its interaction with other drugs. A classic and dangerous combination is cyclosporine with **azole antifungals** (e.g., ketoconazole, itraconazole, fluconazole) [<a href="#ref-1">1</a>]. These drugs are often used to treat fungal infections, which can be a complication of immunosuppression. However, they block the metabolism of cyclosporine, leading to a rapid and significant increase in cyclosporine blood levels. This can quickly push the patient into a toxic range, causing severe kidney and liver damage.

Another significant interaction is with **amphotericin B**, an antifungal drug used for severe systemic fungal infections. This combination carries a high risk of additive nephrotoxicity [<a href="#ref-1">1</a>].

Veterinarians must be meticulous when prescribing any new medication to a pet on cyclosporine. A thorough review of the pet's current medication list is essential to avoid these potentially life-threatening interactions.

---

## Monitoring for Adverse Effects

The most significant adverse effects of cyclosporine are related to its impact on the kidneys and liver.

### Nephrotoxicity (Kidney Damage)

Cyclosporine causes vasoconstriction of the afferent arterioles in the kidney, which reduces blood flow and can lead to a decrease in the glomerular filtration rate (GFR). Over time, this can cause irreversible structural damage to the kidneys, leading to chronic kidney disease (CKD) [<a href="#ref-3">3</a>]. This is a well-known complication in human transplant patients, and it is a major concern for veterinary patients on long-term therapy. In fact, chronic kidney disease is one of the most frequent and severe long-term complications in human liver transplant recipients, with cyclosporine being a major contributor [<a href="#ref-3">3</a>].

**Monitoring:** Your veterinarian will monitor your pet's kidney values (BUN, creatinine, SDMA) and urine specific gravity before starting therapy and periodically throughout treatment. A rise in these values may indicate kidney injury and necessitate a dose reduction or discontinuation of the drug.

### Hepatotoxicity (Liver Damage)

Cyclosporine is metabolized in the liver, and high blood levels can cause direct damage to liver cells [<a href="#ref-1">1</a>]. A predictive model for cyclosporine-associated liver injury in children after stem cell transplantation highlighted that high trough concentrations are a major risk factor for this complication [<a href="#ref-1">1</a>]. The same principle applies to veterinary patients.

**Monitoring:** Liver enzymes (ALT, AST, ALP, GGT) and bilirubin should be checked regularly. If these values become elevated, it may be a sign of cyclosporine-induced liver injury.

### Other Side Effects

- **Gastrointestinal Upset:** Vomiting, nausea, and diarrhea (diarrhoea) are the most common side effects. They are often transient and can be managed by giving the medication with food or splitting the daily dose.
- **Gingival Hyperplasia:** Overgrowth of the gums is a common side effect, particularly in dogs.
- **Hirsutism:** Excessive hair growth can occur.
- **Increased Risk of Infections:** Because cyclosporine suppresses the immune system, pets are at a higher risk of developing bacterial, viral, and fungal infections.

---

## How to Perform Dose Adjustments Safely

Dose adjustments should **only** be made by a veterinarian based on clinical judgment and, ideally, TDM results.

1.  **If Trough Level is Low and the Pet is Not Responding:** The veterinarian may increase the dose by 25-50% and recheck the trough level in 5-7 days.
2.  **If Trough Level is High and the Pet is Experiencing Side Effects:** The veterinarian may decrease the dose or increase the dosing interval (e.g., from every 24 hours to every 36 or 48 hours). The trough level should be rechecked to confirm it has fallen into the therapeutic range.
3.  **If Trough Level is High but the Pet is Stable:** The veterinarian may still reduce the dose to minimize the risk of long-term kidney and liver damage.
4.  **If Trough Level is Low but the Pet is Stable:** The veterinarian may keep the dose the same, as the goal is to use the lowest effective dose.

---

## Unsafe Home Remedies and Owner Actions

**Do not attempt to adjust your pet's cyclosporine dose at home.** This is a prescription medication with a narrow therapeutic index. Making unmonitored changes can lead to either a loss of disease control or severe, life-threatening toxicity.

**Do not give over-the-counter medications without consulting your veterinarian.** Many common human medications, including antacids (like omeprazole or cimetidine) and certain supplements, can interact with cyclosporine.

**Do not stop the medication abruptly.** Cyclosporine is often used for long-term management. Stopping it suddenly can cause a severe and rapid relapse of the underlying immune-mediated disease.

---

## Prevention and Long-Term Management

The goal of therapy is to induce and then maintain remission using the lowest possible effective dose of cyclosporine.

- **Tapering:** Once a pet has been in remission for several weeks to months, the veterinarian will typically begin a slow tapering protocol. This might involve reducing the frequency of administration (e.g., from once daily to every other day) before reducing the actual dose. This process can take many months.
- **Regular Check-ups:** Pets on long-term cyclosporine therapy require regular veterinary check-ups, including blood work, to monitor for silent kidney or liver damage.
- **Lifestyle:** Maintaining a healthy lifestyle, including a balanced diet and routine parasite prevention, is important to support the pet's overall health while on immunosuppressive therapy.

---

## Prognosis

The prognosis for pets on cyclosporine depends entirely on the underlying disease being treated.
- For **atopic dermatitis**, the prognosis is generally good, with most pets achieving significant improvement in their quality of life.
- For **immune-mediated diseases like IMHA or IMT**, the prognosis is guarded to fair. These are life-threatening conditions, and the success of therapy depends on how quickly the immune system is brought under control and whether complications like organ damage or infections occur.
- For **chronic conditions like IBD**, the prognosis is variable. Many pets can achieve long-term remission with a combination of cyclosporine and dietary management. However, some may be refractory to treatment.

---

## Limitations and When to Contact a Veterinarian

This article provides a general overview of cyclosporine dosing and monitoring. It is **not** a substitute for professional veterinary advice. Breed-level information cannot predict how your individual pet will respond to this medication. The optimal dose and monitoring plan for your pet must be determined by a licensed veterinarian.

**Contact your veterinarian immediately if you observe any of the following:**
- **Emergency Red Flags:**
    - Seizures or tremors
    - Sudden collapse or weakness
    - Difficulty breathing
    - Severe, uncontrolled vomiting or diarrhea (diarrhoea) leading to dehydration
    - Signs of a severe infection (high fever, lethargy, not eating)
- **Concerning Signs:**
    - Persistent vomiting or diarrhea (diarrhoea)
    - Decreased appetite or weight loss
    - Increased thirst and urination (possible kidney issues)
    - Yellowing of the gums or skin (jaundice, possible liver issues)

---

## Frequently Asked Questions

### 1. What is the typical starting dose of cyclosporine (Atopica) for a dog with skin allergies?
The typical starting dose is 5 mg/kg given orally once a day, but your veterinarian may adjust this based on your [dog](/knowledge/veterinary-medicine/clinical-methods/dog)'s specific needs and response.

### 2. How is cyclosporine dosed for severe immune-mediated diseases like IMHA?
For life-threatening diseases like IMHA, the dose is often higher, ranging from 5 to 10 mg/kg per day, and is frequently used in combination with other immunosuppressants like corticosteroids.

### 3. What is therapeutic drug monitoring (TDM) and why is it important for cyclosporine?
TDM is the practice of measuring the level of cyclosporine in the blood (usually a trough level) to ensure it is in a range that is both effective and safe, as the drug has a narrow therapeutic window.

### 4. What are the most common side effects of cyclosporine in pets?
The most common side effects are gastrointestinal, including vomiting and diarrhea (diarrhoea). More serious side effects include kidney and liver damage, which is why regular blood monitoring is essential.

### 5. Can I give my pet other medications while they are on cyclosporine?
You must always consult your veterinarian before giving any other medication, including over-the-counter drugs or supplements, as many can interact dangerously with cyclosporine, such as azole antifungals.

### 6. How long does it take for cyclosporine to start working?
For skin conditions, it can take 4 to 6 weeks to see significant improvement. For other immune-mediated diseases, the response time can vary, and your veterinarian will monitor your pet closely.

### 7. How long does a pet need to stay on cyclosporine?
The duration of therapy varies. Some pets may need it for a few months, while others may require lifelong treatment to manage a chronic condition. The goal is always to use the lowest effective dose.

### 8. What should I do if I miss giving my pet a dose of cyclosporine?
If you miss a dose, give it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume the normal schedule. Do not give a double dose. Contact your veterinarian if you have any questions.

---

## Veterinary Disclaimer

**This article is educational and is not a substitute for veterinary diagnosis or treatment.** Always seek the advice of your veterinarian or another qualified animal health provider with any questions you may have regarding a medical condition. Never disregard professional veterinary advice or delay in seeking it because of something you have read in this article.

---


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is the typical starting dose of cyclosporine (Atopica) for a dog with skin allergies?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The typical starting dose is 5 mg/kg given orally once a day, but your veterinarian may adjust this based on your dog's specific needs and response."
      }
    },
    {
      "@type": "Question",
      "name": "How is cyclosporine dosed for severe immune-mediated diseases like IMHA?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "For life-threatening diseases like IMHA, the dose is often higher, ranging from 5 to 10 mg/kg per day, and is frequently used in combination with other immunosuppressants like corticosteroids."
      }
    },
    {
      "@type": "Question",
      "name": "What is therapeutic drug monitoring (TDM) and why is it important for cyclosporine?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "TDM is the practice of measuring the level of cyclosporine in the blood (usually a trough level) to ensure it is in a range that is both effective and safe, as the drug has a narrow therapeutic window."
      }
    },
    {
      "@type": "Question",
      "name": "What are the most common side effects of cyclosporine in pets?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The most common side effects are gastrointestinal, including vomiting and diarrhea. More serious side effects include kidney and liver damage, which is why regular blood monitoring is essential."
      }
    },
    {
      "@type": "Question",
      "name": "Can I give my pet other medications while they are on cyclosporine?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "You must always consult your veterinarian before giving any other medication, including over-the-counter drugs or supplements, as many can interact dangerously with cyclosporine, such as azole antifungals."
      }
    },
    {
      "@type": "Question",
      "name": "How long does it take for cyclosporine to start working?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "For skin conditions, it can take 4 to 6 weeks to see significant improvement. For other immune-mediated diseases, the response time can vary, and your veterinarian will monitor your pet closely."
      }
    },
    {
      "@type": "Question",
      "name": "How long does a pet need to stay on cyclosporine?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The duration of therapy varies. Some pets may need it for a few months, while others may require lifelong treatment to manage a chronic condition. The goal is always to use the lowest effective dose."
      }
    },
    {
      "@type": "Question",
      "name": "What should I do if I miss giving my pet a dose of cyclosporine?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "If you miss a dose, give it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume the normal schedule. Do not give a double dose. Contact your veterinarian if you have any questions."
      }
    }
  ]
}
</script>

## Sources

<a id="ref-1"></a>[<a href="#ref-1">1</a>] [Therapeutic Drug Monitoring-Driven Prediction of Cyclosporine-Associated Liver Injury in Pediatric Thalassemia After Hematopoietic Stem Cell Transplantation.](https://pubmed.ncbi.nlm.nih.gov/42417548/)

<a id="ref-2"></a>[<a href="#ref-2">2</a>] [Prophylaxis of graft-versus-host-disease: Systematic evidence-based recommendations of the Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and the Brazilian society of cellular therapy and bone marrow transplantation (SBTMO).](https://pubmed.ncbi.nlm.nih.gov/42424929/)

<a id="ref-3"></a>[<a href="#ref-3">3</a>] [Rethinking chronic kidney disease risk after liver transplantation.](https://pubmed.ncbi.nlm.nih.gov/42281854/)

<a id="ref-4"></a>[<a href="#ref-4">4</a>] [Intermittent short-term low dose cyclosporine may help break the itch-scratch cycle in uremic pruritus: A retrospective study.](https://pubmed.ncbi.nlm.nih.gov/42376484/)

<a id="ref-5"></a>[<a href="#ref-5">5</a>] [Reduced-Dose PTCy Plus Post-Engraftment Low-Dose ATG for GVHD Prophylaxis in Haploidentical PBSC Transplantation.](https://pubmed.ncbi.nlm.nih.gov/42532275/)

<a id="ref-6"></a>[<a href="#ref-6">6</a>] [Successful Treatment of Adult Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis With Etoposide Guided by Plasma Epstein-Barr Virus DNA Monitoring: A Case Report.](https://pubmed.ncbi.nlm.nih.gov/42421795/)

<a id="ref-7"></a>[<a href="#ref-7">7</a>] [Immunoglobulin A nephropathy with superimposed minimal change disease complicated by acute kidney injury requiring temporary hemodialysis.](https://pubmed.ncbi.nlm.nih.gov/42400865/)

<a id="ref-8"></a>[<a href="#ref-8">8</a>] [Efficacy of low dose of rituximab to treat systemic lupus erythematosus.](https://pubmed.ncbi.nlm.nih.gov/42382748/)

<a id="ref-9"></a>[<a href="#ref-9">9</a>] [Early Remission of Type B Insulin Resistance Syndrome Achieved by Glucocorticoid-based Immunosuppressive Therapy and Visualized by Intermittently Scanned Continuous Glucose Monitoring.](https://pubmed.ncbi.nlm.nih.gov/42366039/)

<a id="ref-10"></a>[<a href="#ref-10">10</a>] [Co-occurrence of Kikuchi-Fujimoto Disease, Systemic Lupus Erythematosus, and Macrophage Activation Syndrome Presenting With Acute Pancreatitis and Myositis in an Adolescent Male Patient.](https://pubmed.ncbi.nlm.nih.gov/42338821/)

<a id="ref-11"></a>[<a href="#ref-11">11</a>] [iTRAQ-based proteomic identification of cyclophilin as a candidate mediator for cyclosporin A-mediated immunomodulation in pearl oysters Pinctada fucata martensii.](https://pubmed.ncbi.nlm.nih.gov/42336300/)

<a id="ref-12"></a>[<a href="#ref-12">12</a>] [Phosphosulindac (OXT-328) restores the suppressed corneal sensitivity in rabbits with dry eye disease: therapeutic implications.](https://pubmed.ncbi.nlm.nih.gov/42317768/)

<a id="ref-13"></a>[<a href="#ref-13">13</a>] [Tocilizumab for the Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease in Children: Two Case Reports and Literature Review.](https://pubmed.ncbi.nlm.nih.gov/42292159/)

<a id="ref-14"></a>[<a href="#ref-14">14</a>] [Eltrombopag Combined With Cyclosporine A in the Treatment of Pediatric Patients With SAA: Establishing the Range for Eltrombopag Concentrations.](https://pubmed.ncbi.nlm.nih.gov/42257533/)

<a id="ref-15"></a>[<a href="#ref-15">15</a>] [The Use of Naltrexone to Successfully Treat Severe Hailey-Hailey Disease.](https://pubmed.ncbi.nlm.nih.gov/42256828/)

<a id="ref-16"></a>[<a href="#ref-16">16</a>] [Adult-onset Still's disease presenting with periorbital erythematous rash and progressive interstitial lung disease.](https://pubmed.ncbi.nlm.nih.gov/42476604/)

<a id="ref-17"></a>[<a href="#ref-17">17</a>] [Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study.](https://pubmed.ncbi.nlm.nih.gov/42387034/)

<a id="ref-18"></a>[<a href="#ref-18">18</a>] [CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases.](https://pubmed.ncbi.nlm.nih.gov/42357300/)

<a id="ref-19"></a>[<a href="#ref-19">19</a>] [Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy.](https://pubmed.ncbi.nlm.nih.gov/42266961/)

## Related Clinical & Scientific Guides

* [Drontal Plus Dewormer: Broad-Spectrum Dose Guide by Weight](/knowledge/veterinary-medicine/calculators-clinical-tools/drontal-plus-dewormer-broad-spectrum-dose-guide-by-weight)
* [Panacur Fenbendazole Dewormer: Dog Fecal Parasite Treatment Schedule](/knowledge/veterinary-medicine/calculators-clinical-tools/panacur-fenbendazole-dewormer-dog-fecal-parasite-treatment-schedule)
* [Prednisolone for Cats: Feline Safe Steroid Dose and Autoimmune](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisolone-for-cats-feline-safe-steroid-dose-and-autoimmune)